
Trial results support US biologics license application for risto-cel
Beam Therapeutics has shared positive topline results from the BEACON Phase I/II study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD. Read More












